• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用无毒溶剂甘油醛制备微球。

Microsphere preparation using the untoxic solvent glycofurol.

机构信息

Laboratory of Pharmaceutical Engineering, Institute of Pharmacy, University of Bonn, Gerhard-Domagk-Str 3, 53121 Bonn, Germany.

出版信息

Pharm Res. 2011 Mar;28(3):563-71. doi: 10.1007/s11095-010-0304-6. Epub 2010 Oct 29.

DOI:10.1007/s11095-010-0304-6
PMID:21049282
Abstract

PURPOSE

At laboratory scale, the most widely applied methods in therapeutic microencapsulation are based on emulsification using organic solvents. Here, glycofurol was proposed as non-toxic solvent to circumvent these inconveniences using a quasi-emulsion extraction method for the preparation of poly (lactide-co-glycolide) microspheres.

METHODS

Matrix polymer and lipophilic drug were dissolved in glycofurol, building the internal phase, and emulsified under stirring into various external phases before microspheres could be obtained and characterized for their pharmacotechnical properties.

RESULTS

Microspheres were spherical with particle diameters around 100 to 200 μm and also showed a monomodal particle size distribution. The internal sponge-like structure was related to an incomplete glycofurol extraction (residual content: 16.9% ± 1.6% of total particle mass), which is, however, no toxicological drawback. The encapsulation rate of several model compounds increased with rising partition coefficient (Ibuprofen: 1.9% ± 0.6%, Ritonavir: 11.2% ± 0.4%, Lopinavir: 14.0% ± 2.2%, Sudan III: 28.3% ± 0.4%) due to the decreasing solubility in the external phase. In-vitro release kinetics were varying from a complete release after 4 h for Ritonavir to 3 weeks for Sudan III.

CONCLUSION

This new method was confirmed to be suitable for the preparation of microspheres with the use of a non-toxic solvent and to allow for the entrapment of lipophilic actives and their controlled release.

摘要

目的

在实验室规模下,治疗性微囊化最广泛应用的方法基于使用有机溶剂的乳化作用。在这里,提议使用无毒溶剂甘油醛来规避这些不便,采用准乳液萃取法制备聚(乳酸-共-乙醇酸)微球。

方法

基质聚合物和疏水性药物溶解在甘油醛中,形成内相,并在搅拌下乳化到各种外相中,然后得到微球,并对其药物技术性质进行了表征。

结果

微球呈球形,粒径约为 100 至 200 μm,且具有单峰粒径分布。内部海绵状结构与不完全的甘油醛萃取有关(残留含量:占总粒子质量的 16.9%±1.6%),但这不是毒理学上的缺点。几种模型化合物的包封率随分配系数的升高而增加(布洛芬:1.9%±0.6%,利托那韦:11.2%±0.4%,洛匹那韦:14.0%±2.2%,苏丹红 III:28.3%±0.4%),这是由于在外部相中溶解度降低。体外释放动力学从利托那韦 4 小时完全释放到苏丹红 III 的 3 周不等。

结论

该新方法被证实适用于使用无毒溶剂制备微球,并可包封疏水性活性物质及其控制释放。

相似文献

1
Microsphere preparation using the untoxic solvent glycofurol.使用无毒溶剂甘油醛制备微球。
Pharm Res. 2011 Mar;28(3):563-71. doi: 10.1007/s11095-010-0304-6. Epub 2010 Oct 29.
2
Preparation of PLGA Microspheres Using the Non-Toxic Glycofurol as Polymer Solvent by a Modified Phase Inversion Methodology.采用改良相转化法以无毒的丙二醇甲醚醋酸酯为聚合物溶剂制备聚乳酸-羟基乙酸共聚物微球
Polymers (Basel). 2024 Feb 4;16(3):434. doi: 10.3390/polym16030434.
3
Encapsulation of water-soluble drugs by an o/o/o-solvent extraction microencapsulation method.水相药物的 o/o/o 溶剂萃取微囊化包封。
Int J Pharm. 2011 May 16;409(1-2):89-95. doi: 10.1016/j.ijpharm.2011.02.029. Epub 2011 Feb 26.
4
Preparation of PLGA microparticles by an emulsion-extraction process using glycofurol as polymer solvent.采用二缩丙二醇甲醚醋酸酯作为聚合物溶剂,通过乳液萃取法制备聚乳酸-羟基乙酸共聚物微粒。
Pharm Res. 2004 Dec;21(12):2384-91. doi: 10.1007/s11095-004-7693-3.
5
pH-sensitive microparticles prepared by an oil/water emulsification method using n-butanol.采用正丁醇通过油/水乳化法制备的pH敏感微粒。
Int J Pharm. 2009 Jun 22;375(1-2):61-6. doi: 10.1016/j.ijpharm.2009.04.006. Epub 2009 Apr 11.
6
A poly(D,L-lactide-co-glycolide) microsphere depot system for delivery of haloperidol.
J Control Release. 1998 Nov 13;55(2-3):203-12. doi: 10.1016/s0168-3659(98)00056-x.
7
Preparation of polymeric particles in CO(2) medium using non-toxic solvents: formulation and comparisons with a phase separation method.使用无毒溶剂在 CO(2)介质中制备聚合物颗粒:配方及与相分离法的比较。
Eur J Pharm Biopharm. 2012 Nov;82(3):498-507. doi: 10.1016/j.ejpb.2012.08.005. Epub 2012 Aug 29.
8
Solvent hydrolysis rate determines critical quality attributes of PLGA microspheres prepared using non-volatile green solvent.溶剂水解速率决定了使用非挥发性绿色溶剂制备的 PLGA 微球的关键质量属性。
J Biomater Sci Polym Ed. 2018 Jan;29(1):35-56. doi: 10.1080/09205063.2017.1398993. Epub 2017 Nov 6.
9
Lappaconitine-loaded microspheres for parenteral sustained release: effects of formulation variables and in vitro characterization.用于肠胃外缓释的高乌甲素微球:制剂变量的影响及体外特性研究
Pharmazie. 2011 Sep;66(9):654-61.
10
Biodegradable, somatostatin acetate containing microspheres prepared by various aqueous and non-aqueous solvent evaporation methods.通过各种水相和非水相溶剂蒸发法制备的可生物降解的含醋酸生长抑素微球。
Eur J Pharm Biopharm. 1998 Jan;45(1):75-82. doi: 10.1016/S0939-6411(97)00125-2.

引用本文的文献

1
Preparation of PLGA Microspheres Using the Non-Toxic Glycofurol as Polymer Solvent by a Modified Phase Inversion Methodology.采用改良相转化法以无毒的丙二醇甲醚醋酸酯为聚合物溶剂制备聚乳酸-羟基乙酸共聚物微球
Polymers (Basel). 2024 Feb 4;16(3):434. doi: 10.3390/polym16030434.
2
Sustainability in Drug and Nanoparticle Processing.药物与纳米颗粒加工中的可持续性。
Handb Exp Pharmacol. 2024;284:45-68. doi: 10.1007/164_2023_659.
3
Isotropic conductive paste for bioresorbable electronics.用于生物可吸收电子器件的各向同性导电胶。

本文引用的文献

1
Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles.将疏水性药物包裹于聚乳酸/聚乳酸-羟基乙酸共聚物微粒中的原理。
Int J Pharm. 2008 Dec 8;364(2):298-327. doi: 10.1016/j.ijpharm.2008.04.042. Epub 2008 May 7.
2
A novel preparation method for PLGA microspheres using non-halogenated solvents.一种使用非卤代溶剂制备聚乳酸-羟基乙酸共聚物(PLGA)微球的新方法。
J Control Release. 2008 Aug 7;129(3):223-7. doi: 10.1016/j.jconrel.2008.04.008. Epub 2008 Apr 22.
3
Formation mechanism and release behavior of poly(epsilon-caprolactone) microspheres containing disodium norcantharidate.
Mater Today Bio. 2023 Jan 4;18:100541. doi: 10.1016/j.mtbio.2023.100541. eCollection 2023 Feb.
4
Adjustable Thermo-Responsive, Cell-Adhesive Tissue Engineering Scaffolds for Cell Stimulation through Periodic Changes in Culture Temperature.可调温响应、细胞黏附组织工程支架,通过周期性改变培养温度来刺激细胞。
Int J Mol Sci. 2022 Dec 29;24(1):572. doi: 10.3390/ijms24010572.
5
Recent advances in the formulation of PLGA microparticles for controlled drug delivery.用于控释给药的聚乳酸-羟基乙酸共聚物(PLGA)微粒制剂的最新进展。
Prog Biomater. 2020 Dec;9(4):153-174. doi: 10.1007/s40204-020-00139-y. Epub 2020 Oct 15.
6
Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates.聚氨基甲基丙烯酸酯共凝聚体经口递释低分子量肝素。
Pharm Res. 2013 Aug;30(8):1990-8. doi: 10.1007/s11095-013-1043-2. Epub 2013 May 7.
7
Application of hydroxyapatite nanoparticles in development of an enhanced formulation for delivering sustained release of triamcinolone acetonide.羟基磷灰石纳米粒子在开发增强型曲安奈德缓释制剂中的应用。
Int J Nanomedicine. 2011;6:825-33. doi: 10.2147/IJN.S18045. Epub 2011 Apr 19.
含去甲斑蝥酸钠的聚(ε-己内酯)微球的形成机制与释放行为
Eur J Pharm Biopharm. 2008 Aug;69(3):1176-81. doi: 10.1016/j.ejpb.2008.02.020. Epub 2008 Feb 29.
4
PLGA-based drug delivery systems: importance of the type of drug and device geometry.基于聚乳酸-羟基乙酸共聚物的药物递送系统:药物类型和装置几何形状的重要性。
Int J Pharm. 2008 Apr 16;354(1-2):95-103. doi: 10.1016/j.ijpharm.2007.10.030. Epub 2007 Oct 30.
5
Process and formulation variables in the preparation of injectable and biodegradable magnetic microspheres.可注射及可生物降解磁性微球制备过程中的工艺和配方变量。
Biomagn Res Technol. 2007 Apr 4;5:2. doi: 10.1186/1477-044X-5-2.
6
A novel in situ forming drug delivery system for controlled parenteral drug delivery.一种用于可控非肠道给药的新型原位形成药物递送系统。
Int J Pharm. 2007 Mar 6;332(1-2):107-14. doi: 10.1016/j.ijpharm.2006.09.033. Epub 2006 Sep 26.
7
Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma.采用常规高效液相色谱法同时测定人血浆中7种HIV蛋白酶抑制剂和非核苷类逆转录酶抑制剂依非韦伦。
Biol Pharm Bull. 2005 Jul;28(7):1286-90. doi: 10.1248/bpb.28.1286.
8
Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.
Bioorg Med Chem Lett. 2005 Aug 15;15(16):3767-70. doi: 10.1016/j.bmcl.2005.05.087.
9
From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors.从SAR到比较性QSAR:疏水性在4-羟基-5,6-二氢吡喃-2-酮HIV-1蛋白酶抑制剂设计中的作用
Bioorg Med Chem. 2005 Jun 2;13(12):4078-84. doi: 10.1016/j.bmc.2005.03.049. Epub 2005 Apr 25.
10
Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.世界卫生组织基本药物的分子特性及临时生物药剂学分类
Mol Pharm. 2004 Jan 12;1(1):85-96. doi: 10.1021/mp034006h.